6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity

Background-6-Mercaptopurine (6-MP) has confirmed short and longterm efficacy in the treatment of IBD. However, the relation between its metabolism, efficacy, and side effects is not well understood. Aims-To assay 6-MP metabolites and to correlate levels with drug compliance, disease activity, and adverse effects of treatment. Patients-Heparinised blood was obtained prior to daily administration of 6-MP in 25 adolescent Crohn's disease patients (14 ileocolitis, 11 colitis) receiving 1.2 (range 0.4-1.6) mg/kg/day for a mean of 17 (range 4-65) months. Methods-Erythrocyte free bases 6-thioguanine (6-TG) and 6-methyl-mercaptopurine (6-MMP) were measured (pmol/ 8 x 10(8) red blood cells) using reverse phase high performance liquid chromatography. Results-Disease activity (modified Harvey-Bradshaw index) improved significantly with 6-MP (p=0.001). Clinical remission was achieved in 72% of patients, who stopped taking prednisone, or were successfully weaned to a low alternate day dose (<0.4 mg/kg/OD). Remission correlated well with erythrocyte 6-TG (p<0.05), but not 6-MMP levels. Neutropenia was associated with 6-MP use (p<0.005), but did not correlate with erythrocyte 6-MP metabolite levels. One patient refractory to 6-MP had 6-TG, but no measureable 6-MMP production, suggesting deficient thiopurine methyl-transferase activity or poor compliance. 6-MP induced complications (hepatitis, pancreatitis, and marrow suppression) were generally associated with increased 6-MMP levels. Conclusions-These results suggest that high performance liquid chromatography measurement of erythrocyte 6-MP metabolites may provide a quantitative assessment of patient responsiveness and compliance to treatment. The data support an immunosuppressive role for 6-TG, and potential cytotoxicity of raised 6-MMP levels.